Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen
170791-09-0CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(-c2ccccc2-c2nnnn2C(c2ccccc2)(c2ccccc2)c2ccccc2)cc1MOHQWFWIPOOTGV-UHFFFAOYSA-NSicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
This chemical does not meet GHS hazard criteria for 57.1% (4 of 7) of all reports.
Warning
H302 (14.3%): Harmful if swallowed [Warning Acute toxicity, oral]
P203, P260, P261, P263, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P317, P318, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 7 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
VerwendenTrityl Candesartan Cilexetil (Candesartan Cilexetil EP Impurity H) is an impurity of Candesartan (C175575), an angiotensin II type-1 receptor antagonist and used in treatment of congestive heart failure.
170791-09-0DTXSID901308612